An Incisive, In-depth Analysis on the Viscosupplementation Market
This study offers a comprehensive, 360 degree analysis on the Viscosupplementation market, bringing to fore insights that can help stakeholders identify the opportunities as well as challenges. It tracks the global Viscosupplementation market across key regions, and offers in-depth commentary and accurate quantitative insights. The study also includes incisive competitive landscape analysis, and provides key recommendations to market players on winning imperatives and successful strategies.
Viscosupplementation Market - Key Research Findings
Global viscosupplementation market size in 2018 – Nearly US$ 2,300 Mn
The viscosupplementation market is expected to grow at an approximate CAGR of 5.0% over 2019-2029.
North America and Europe are expected to remain the largest regional markets for viscosupplementation products.
North America and Europe are the leading regions in the viscosupplementation market owing to the increasing adoption of viscosupplementation products for osteoarthritis and increasing number of clinical trials for the development of viscosupplementation products for different joints. Gains will be driven by viscosupplementation’s viability as an effective mode of treatment that can delay knee replacement surgery.
The three injection segment is expected to remain the most preferred product type segment of the viscosupplementation market
The growth of this segment can be primarily attributed to the global growth of the osteoarthritis treatment market. Some of the factors, such as cost-effectiveness and rising patient awareness about the benefits of viscosupplementation procedures, are expected to propel the growth of the viscosupplementation market.
Top 3 Factors Shaping the Viscosupplementation Market
Launch of New Products and Increase in the Number of Distribution Agreements are Among the Major Trends in the Viscosupplementation Market
Key market players, such as Anika therapeutics, Bioventus LLC, Seikagaku Corporation, and Zimmer Biomet, are focusing on the expansion of viscosupplementation product portfolio through distribution agreements and the launch of the new products. For example-
In March 2019, Seikagaku launched HyLink, an intra-articular single-injection viscosupplement for the treatment of knee osteoarthritis in Italy
In February 2018, Bioventus LLC entered into an extension of its agreement with Seikagaku Corporation to continue the distribution and marketing of SUPARTZ FX in the U.S.
Rising Patient Pool Suffering from Osteoarthritis is expected to Create Strong Demand for Viscosupplementation Products
According to the Centers for Disease Control and Prevention, osteoarthritis affected more than 30 million U.S. adults during 2018, and it has also been estimated that 70 million people are likely to suffer from osteoarthritis by 2040. Increase in the population suffering from osteoarthritis is creating high demand for osteoarthritis treatment and pain management products, which is expected to result in the robust growth of the viscosupplementation market.
Introduction of Combination Products is Propelling the Growth of the Viscosupplementation Market Over the Forecast Period
Manufacturers are constantly improving their pipeline capabilities and enhancing their well-established presence in the intra-articular hyaluronic acid injection market with the introduction of new combination hyaluronic acid products. Due to the excellent physiochemical properties of hyaluronic acid, it can be easily combined with other pharmaceuticals such as corticosteroids.
In 2016, Anika Therapeutics launched the ‘Cingal’ combination of hyaluronic acid products in Canada. Anika Therapeutics is recently focusing on receiving approval for Cingal in the U.S. market.
Viscosupplementation Market Structure Analysis
The global viscosupplementation market is a fragmented market owing to the presence of a number of big market players and regional players
Most of the key players maintain a strategic focus on the development of distribution partnerships and agreement for global market expansion
Manufacturers are focusing to receiving FDA approval for a combination hyaluronic acid injection and viscosupplementation for other joints except for knee joints in the U.S. market, as no viscosupplementation products are approved for other joints osteoarthritis treatment except knees in the U.S.
Some of the top manufacturers that contribute a high revenue share in the viscosupplementation market are Sanofi SA, Fidia Farmaceutici S.p.A., Seikagaku Corporation, Ferring B.V., and Sanofi SA.
Distribution and marketing synergies between companies expected to exploit the growth prospects of the viscosupplementation market.
Major players in the viscosupplementation market, such as Anika Therapeutics, Zimmer Biomet, Bioventus LLC, Depuy Synthesis, etc., are employing synergistic methods for the co-marketing and co-promotion of their products with other companies. These synergies between partners are presenting an instant growth impact as compared to acquisitions and mergers.
In November 2016, Zimmer Biomet signed an exclusive distribution agreement with Seikagaku Corporation for the sales of VISCO-3 in the U.S. market. Zimmer Biomet also distributes Seikagaku Corporation’s Gel-One Cross-linked Hyaluronate product.
FMI has compiled a study on the viscosupplementation market, which offers an analysis and forecast of the viscosupplementation market in its publication titled ‘Viscosupplementation Market: Global Industry Analysis 2014 – 2018 and Opportunity Assessment 2019 – 2029.’
Viscosupplementation Market - Report Introduction
This report on the viscosupplementation market covers some of the key influencing factors on the demand and supply of viscosupplementation injections over the next several years. An in-depth review of the growth drivers, potential challenges, unique trends, and opportunities for the market participants is expected to equip readers to fully comprehend the overall landscape of the viscosupplementation market. The report on the viscosupplementation market also covers an analysis of the key regions and countries of particular interest, which are estimated to become frontrunners or remain laggards over the forecast period. The report covers a historical analysis of the market from 2014 to 2018, and provides forecasts from 2019 to 2029 in terms of revenue in US$.
Osteoarthritis (OA) is a chronic degenerative diseases and is characterized by gradual loss of cartilage. OA of knee is more prevalent and often incapacitating condition that can be treated in a variety of ways, resulting in a range of clinical outcomes. Intra Articular injection of hyaluronic acid also referred to as viscosupplementation is widely used for symptomatic knee osteoarthritis. Viscosupplementation was first used in Europe and Asia, and was approved by the U.S. Food and Drug Administration in 1997.These injections are sold under various brand names such as Hyalgan, Orthovisc, Synvisc, Gel-One, Supartz, and Euflexxa.
This report on the viscosupplementation market has been broken down into different chapters to enhance clarity and provide context.
A brief executive summary at the beginning of the report consists of some of the key findings of the study on the viscosupplementation market, as well as market estimates and growth rates for important segments.
Scope of the Report
The following chapter presents the definitions and scope of the study, as well as the coverage in terms of the way in which the viscosupplementation market is structured. Subsequently, the chapter on the market background contains relevant economic indicators, such as per capita healthcare spending, which elaborate the dynamics impacting the viscosupplementation market, as well as provides an explanation of the factors considered important to develop forecasts and estimates.
The following chapters dive deep into the global viscosupplementation market, covering detailed information based on product type, and end user. The next set of chapters provide a region-wise analysis and forecasts of the Viscosupplementation market, which cover the vital aspects of the market in North America, Latin America, Europe, East Asia, South Asia, Oceania, and the Middle East and Africa.
A dashboard view of some of the key companies operating in the viscosupplementation market in terms of their offerings, regional presence, and other metrics is a precursor to the detailed profiles of these participants, which include their financial information, strategy overview, and products offered, as well as analyst commentary. Some of the key players analyzed in the viscosupplementation market report include Anika Therapeutics Inc., Sanofi S.A., Zimmer Biomet Holdings Inc., Bioventus LLC, Ferring B.V., Seikagaku Corporation, Seikagaku Corporation, Chugai Pharmaceutical Co., Ltd., Mylan N.V. and among others.
To develop the estimates for the viscosupplementation market, the global adoption of viscosupplementation products was taken into account, which was followed by tracking key players and their product offering globally. This is then cross-referenced with the revenue generated from the sales of viscosupplementation for top companies globally.
Our team of analysts reviews and interpret data from a variety of sources. The data attributed to ‘FMI’ is derived by using a combination of various approaches, which are then consolidated, interpreted, and extrapolated by FMI analysts. Data is sourced from government statistics, trade associations, company annual reports, investor presentations, press articles & directories, technical publications, and online databases, which are cross-referenced with FMI’s reports and internal repository of data to filter and validate the collected information. The intelligence gathered from desk research is supplemented by extensive interviews with selected key expert participants across the value chain not only to gain information specific to their role and operations, but also to obtain their perspective and insights of the issues impacting the viscosupplementation market.